blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3100724

EP3100724 - MEDICINE FOR PREVENTING ISCHEMIC DISEASES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.09.2023
Database last updated on 20.07.2024
FormerExamination is in progress
Status updated on  11.03.2019
FormerRequest for examination was made
Status updated on  04.11.2016
FormerThe international publication has been made
Status updated on  02.11.2016
Most recent event   Tooltip01.09.2023Application deemed to be withdrawnpublished on 04.10.2023  [2023/40]
Applicant(s)For all designated states
JX Nippon Oil & Energy Corporation
1-2, Otemachi, 1-chome
Chiyoda-ku
Tokyo 100-8162 / JP
[2016/49]
Inventor(s)01 / HARA, Hideaki
c/o Gifu Pharmaceutical University
25-4
Daigakunishi 1-chome
Gifu-shi Gifu 501-1196 / JP
02 / ISHIBASHI, Takashi
c/o JX Nippon Oil & Energy Corporation
1-2, Otemachi 1-chome
Chiyoda-ku
Tokyo 100-8162 / JP
 [2016/49]
Representative(s)Altmann Stößel Dick Patentanwälte PartG mbB
Theodor-Heuss-Anlage 2
68165 Mannheim / DE
[N/P]
Former [2016/49]Herzog, Fiesser & Partner Patentanwälte PartG mbB
Dudenstrasse 46
68167 Mannheim / DE
Application number, filing date14880497.422.10.2014
[2016/49]
WO2014JP78677
Priority number, dateJP2014001611830.01.2014         Original published format: JP 2014016118
[2016/49]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015114900
Date:06.08.2015
Language:JA
[2015/31]
Type: A1 Application with search report 
No.:EP3100724
Date:07.12.2016
Language:EN
[2016/49]
Search report(s)International search report - published on:JP06.08.2015
(Supplementary) European search report - dispatched on:EP03.08.2017
ClassificationIPC:A61K31/122, A23L33/10, A23L2/52, A61K35/74, A61P27/02, A61P27/06
[2016/49]
CPC:
A61K31/122 (EP,KR,US); A23L33/10 (EP,KR,US); A23L33/105 (EP,US);
A23L33/135 (KR); A23L33/155 (EP,US); A61K35/74 (EP,KR,US);
A61K45/06 (EP,KR,US); A61P27/02 (EP); A61P27/06 (EP);
A61P3/10 (EP); A61P9/10 (EP); A61P9/12 (EP);
A23V2002/00 (KR,US); A23V2200/30 (KR); A61K2300/00 (KR) (-)
C-Set:
A61K31/122, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/49]
TitleGerman:MEDIKAMENT ZUR VORBEUGUNG VON ISCHÄMISCHEN KRANKHEITEN[2016/49]
English:MEDICINE FOR PREVENTING ISCHEMIC DISEASES[2016/49]
French:MÉDICAMENT POUR LA PRÉVENTION DE MALADIES ISCHÉMIQUES[2016/49]
Entry into regional phase19.08.2016Translation filed 
19.08.2016National basic fee paid 
19.08.2016Search fee paid 
19.08.2016Designation fee(s) paid 
19.08.2016Examination fee paid 
Examination procedure19.08.2016Examination requested  [2016/49]
19.08.2016Date on which the examining division has become responsible
21.02.2018Amendment by applicant (claims and/or description)
14.03.2019Despatch of a communication from the examining division (Time limit: M04)
22.07.2019Reply to a communication from the examining division
03.05.2023Application deemed to be withdrawn, date of legal effect  [2023/40]
25.05.2023Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2023/40]
Fees paidRenewal fee
24.10.2016Renewal fee patent year 03
23.10.2017Renewal fee patent year 04
26.10.2018Renewal fee patent year 05
25.10.2019Renewal fee patent year 06
23.10.2020Renewal fee patent year 07
23.10.2021Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.10.202209   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]JP2008179632  (FUJI CHEM IND CO LTD) [X] 1-15 * paragraphs [0001] , [0002] , [0004] , [0010] - [0048] *[Y] 14,15;
 [XY]EP2192191  (NIPPON OIL CORP [JP]) [X] 1-13 * paragraphs [0001] , [0002] - [0007] - [0 10] - [0029] * * example -; claim - * [Y] 14,15
International search[X]WO9613255  (UNIV ILLINOIS [US]);
 [X]JPH10155459  (SUNTORY LTD, et al);
 [A]JP2006008720  (YAMAHA MOTOR CO LTD);
 [X]JP2012025712  (JX NIPPON OIL & ENERGY CORP);
 [X]  - OTSUKA T. ET AL., "The protective effects of a dietary carotenoid, astaxanthin, against light- induced retinal damage", J.PHARMACOL.SCI., (2013), vol. 123, pages 209 - 218, XP055217499

DOI:   http://dx.doi.org/10.1254/jphs.13066FP
 [X]  - YASUNORI NAGAKI ET AL., "Astaxanthin no Momaku Kekkan Ketsuryuryo ni Oyobosu Eikyo", JOURNAL OF CLINICAL THERAPEUTICS & MEDICINES, (2005), vol. 21, no. 5, pages 537 - 542, XP008183928
 [X]  - YOSHIMI NAKASHIMA ET AL., "Astaxanthin Oyobi Zeaxanthin no Sanka Stress ni yoru Momaku Shogai ni Taisuru Koka", ABSTRACTS OF ANNUAL MEETING OF PHARMACEUTICAL SOCIETY OF JAPAN, (2007), vol. 127 TH, no. 4, pages 114, 30P1 - PM133, XP008183897
by applicantJP2009050237
 JP2014016118
    - OGISHIMA H. ET AL., "Ligation of the Pterygopalatine and External Carotid Arteries Induces Ischemic Damage in the Murine Retina", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, (2011), vol. 52, no. 13, pages 9710 - 9720
    - MURINE RETINA, INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, (2011), vol. 52, no. 13, pages 9710 - 9720
    - NAKAJIMA Y. ET AL., "Zeaxanthin, a Retinal Carotenoid, Protects Retinal Cells against Oxidative Stress", CURRENT EYE RESEARCH, (2009), vol. 34, pages 311 - 318
    - OTSUKA T. ET AL., "The Protective Effects of a Dietary Carotenoid, Astaxanthin, Against Light-Induced Retinal Damage", JOURNAL OF PHARMACOLOGICAL SCIENCES, (2013), vol. 123, no. 3, pages 209 - 218
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.